{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:34:06Z","timestamp":1760646846159,"version":"3.37.3"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chronic hepatitis C treatment with direct acting antiviral (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>) therapy during incarceration is an attractive option, due to its short duration and to the possibility of directly observed treatment or supervision. The aim of this study is to compare the effectiveness and rates of discontinuation of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> treatment in prisoners and nonprisoners. We studied all patients treated in the 10 prisons of Catalonia and at 3 public hospitals in the Barcelona area between 1 January 2015 and 30 April 2016. We analysed sustained viral response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>) and rates of discontinuation through intention\u2010to\u2010treat and modified\u2010intention\u2010to\u2010treat analyses, the latter excluding discontinuations due to release from prison. One hundred and eighty\u2010eight inmates and 862 noninmates were included. Prisoners were significantly younger than nonprisoners, with higher proportions of men, drug users, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection, genotypes 1a and 3 and more treatment with psychiatric drugs. Overall, 98.4% of patients completed treatment. The discontinuation rate was low, but higher in inmates (3.7% vs 1.2% noninmates; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.003) and in community patients &gt;65\u00a0years old (2.8% vs 1.2% in under 65\u00a0seconds; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.008). Among the inmates, 7 (42.8%) discontinuations were due to release. <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> was 93.1% in inmates vs 96.5% in noninmates (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.08) by intention\u2010to\u2010treat and 95.1% vs 96.5% (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.37) by modified intention\u2010to\u2010treat. Virologic failure rates were similar (3.8% vs 3% in noninmates; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.60). <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>, virologic failure and discontinuation rates were similar in inmates and noninmates. Currently, prisons are considered a priority for the implementation of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>. Improved coordination between penitentiary and community health systems would help to ensure therapeutic continuity in released prisoners.<\/jats:p>","DOI":"10.1111\/jvh.12940","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T07:55:05Z","timestamp":1527753305000},"page":"1280-1286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of effectiveness and discontinuation of interferon\u2010free therapy for hepatitis C in prison inmates and noninmates"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-9370","authenticated-orcid":false,"given":"A.","family":"Marco","sequence":"first","affiliation":[{"name":"Prison Health Program Catalan Institute of Health  Barcelona Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roget","sequence":"additional","affiliation":[{"name":"Hepatology Unit Consorci Sanitari  Terrassa Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit Parc Taul\u00ed Hospital Universitari Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT Universitat Aut\u00f2noma de Barcelona  Sabadell Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Forn\u00e9","sequence":"additional","affiliation":[{"name":"Instituto Carlos III CIBERehd  Madrid Spain"},{"name":"Digestive Disease Department Hospital Universitari M\u00fatua Terrassa Universitat Central de Barcelona  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Planella","sequence":"additional","affiliation":[{"name":"Health Services of Ponent Penitentiary Centre  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Miquel","sequence":"additional","affiliation":[{"name":"Instituto Carlos III CIBERehd  Madrid Spain"},{"name":"Hepatology Unit Digestive Disease Department Parc Taul\u00ed Hospital Universitari Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT Universitat Aut\u00f2noma de Barcelona  Sabadell Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Hepatology Unit Consorci Sanitari  Terrassa Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Navarro","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit Parc Taul\u00ed Hospital Universitari Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT Universitat Aut\u00f2noma de Barcelona  Sabadell Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gallego","sequence":"additional","affiliation":[{"name":"Health Services of Quatre Camins Penitentiary Centre  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vergara","sequence":"additional","affiliation":[{"name":"Instituto Carlos III CIBERehd  Madrid Spain"},{"name":"Hepatology Unit Digestive Disease Department Parc Taul\u00ed Hospital Universitari Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT Universitat Aut\u00f2noma de Barcelona  Sabadell Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"In and Out of Prison Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6428a2"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12350"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310332"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.9.30476"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102893.2011.01499.x"},{"key":"e_1_2_7_7_1","unstructured":"World Health Organization.Global health sector strategy on viral hepatitis 2016\u20102021. Available at:http:\/\/apps.who.int\/iris\/bitstream\/10665\/250578\/1\/WHO-HIV-2016.06-spa.pdf. Accessed: May 8 2017."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30075-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i21.2323"},{"key":"e_1_2_7_10_1","unstructured":"Departament de Just\u00edcia.Descriptors estad\u00edstics serveis penitenciaris. Available in:http:\/\/www.gencat.cat\/justicia\/estadistiques_serveis_penitenciaris\/1_pob.html. Accessed: June 16 2017."},{"volume-title":"International Statistical Classification of Diseases and Related Health Problems (WHO ICD\u201010)","year":"2015","author":"World Health Organization","key":"e_1_2_7_11_1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2010.tb03605.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1157\/13094351"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/591707"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25770"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.147629"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/767540"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2004.056150"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1102-x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28609"},{"key":"e_1_2_7_21_1","unstructured":"McDonaldL CragieA SchulbergJ et\u00a0al.Outcomes of treatment for hepatitis C virus infection in the prison setting. Amsterdam: The International Liver Congress (EASL) abstract ILC2017\u2010RS\u20102862 2017."},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","unstructured":"Bouteille\u2010GailletM DulioustA BocquentinM et\u00a0al.Feasibility of anti\u2010HCV direct acting anti\u2010viral agents in French prison settings. Amsterdam: The International Liver Congress (EASL) ILC2017\u2010RS\u20103828 2017.","DOI":"10.1016\/S0168-8278(17)31979-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0602"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28497"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.109-5181"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.0296"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27194"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000179"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12580"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000163"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29005"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30071-7"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.047"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.157"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D252"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T17:11:42Z","timestamp":1694884302000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/jvh.12940"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12940","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"2017-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}